Unbiased Analysis of Today's Healthcare Issues
The RE-AIM framework developed by Glasgow et al. (1999) has five evaluation components. Reach: share of people from a given population who participate in a program and their characteristics. For instance, organizational reach with stakeholders could be indirect, intended or direct. Reach is the number of participants in the program divided by the size of…
That is the question posed by a paper by Wang, Sreedhara and Schneeweiss (2022). The authors replicate the findings from n=250 real-world data studies. The studies were replicated using 3 datasets: (i) Optum Clinformatics claims data, (ii) IBM MarketScan Research Database claims data, Medicare fee-for-service claims data, and (iii) CPRD electronic health records. Key paper…
Interesting study from Nelson-Coffey et a. (2023) showing the positive impact of both felt and expressed gratitude. First, in a 7-day daily experience study conducted in 2018 (N = 270), daily gratitude predicted greater well-being and family functioning, controlling for daily happiness, coder-rated care difficulty, and sociodemographics. Second, in a short-term longitudinal experiment conducted in…
That is the finding from a study by Jia et al. (2023) published last week. The authors find that: Among 4003 eligible RCTs [randomized controlled trials], 1241 studies (31.0%) cited Cochrane reviews, 1698 studies (42.4%) cited prior non-Cochrane reviews, and 2265 studies (56.6%) cited either type of systematic review or both; 1738 RCTs (43.4%) cited…
In short, the answer is ‘no’. The full rationale is here, but here is an excerpt from their policy: Nonhuman artificial intelligence, language models, machine learning, or similar technologies do not qualify for authorship.If these models or tools are used to create content or assist with writing or manuscript preparation, authors must take responsibility for…
In drug development, clinical trials typically aim for a population that is representative of the patients who would be eligible for the treatment. While randomized controlled trials (RCTs) typically focus on measuring the average health impact of a drug across this population, a paper Basu and Gurjal (2020) argue that treatment effect heterogeneity and self-selection…
Where X can be basically any task. Likely your answer is that you are pretty good at X. In fact, you probably think you are above average. There is an explanation for this: the Dunning-Kruger effect. This is a bias where people generally believe they are better at a task than they are. This effect…
Today I put together the journal round-up for the Academic Health Economists’ blog, one of my favorite reads. I review three papers: Understanding price growth in the market for targeted oncology therapies. American Journal of Managed Care [PubMed] Published 14th June 2019 Do cancer treatments have option value? Real‐world evidence from metastatic melanoma. Health Economics [PubMed]…
According to a paper by Moskatel and Slutsky (2019), the answer appears to be ‘yes’. In this paper, we ask whether UberX’s entry into a city caused substitution away from traditional ambulances for low‐risk patients, reducing overall volume. Using a city‐panel over‐time and leverage that UberX enter markets sporadically over multiple years, we find that…
At first this seems like an easy question to answer: catastrophic health care costs mean lots of money. But how do you define a lot? A million dollars? Ten thousand dollars? A hundred dollars? One question is, should catastrophic be measured in absolute or relative terms. For instance, the a ten thousand dollar cost may…